Prediction Of Adverse Outcomes Following A Fragility Fracture
Funder
National Health and Medical Research Council
Funding Amount
$148,426.00
Summary
Individuals with an existing fracture are at increased risk of adverse outcomes such as re-fracture and premature mortality, but it is not clear why. We propose to evaluate risk factors, and prognostic models, for predicting the risk of adverse outcomes. We also propose to develop a quantitative risk-benefit framework for evaluating the clinical utility of such prognostic models and help ensure that therapies appropriately address real-life experience of osteoporotic patients.
Identifying Novel Susceptibility Loci For Osteoporosis Through Whole Genome Sequencing
Funder
National Health and Medical Research Council
Funding Amount
$623,969.00
Summary
Our highly successful genome-wide studies of bone mineral density (a risk factor for osteoporosis) have highlighted 60 loci relevant to the disease. However, a substantial amount of genetic variance remains unexplained. This project will focus on less common variants that have larger effect sizes and are relevant to osteoporosis, but are not well studied by approaches such as high-density SNP arrays and genome-wide association studies.
HDL Elevation And Glucose Metabolism: A Mechanistic Proof-of-Concept Intervention Trial In Pre-Diabetes
Funder
National Health and Medical Research Council
Funding Amount
$507,974.00
Summary
This clinical trial will investigate a new treatment strategy for type 2 diabetes. Building on our novel discovery that HDL (good cholesterol) lowers blood glucose, we will test whether HDL elevation over a month with a new drug (RVX-208) can improve glucose control in patients with pre-diabetes. If positive, these studies will support new therapeutic approaches to raise levels of circulating HDL for indications beyond vascular disease to manage type 2 diabetes.
Monitoring Bone Loss And Response To Therapy Through Bone Material And Structural Composition
Funder
National Health and Medical Research Council
Funding Amount
$696,111.00
Summary
Millions of scripts are filled for treatment of osteoporosis. However, there is no way of knowing if these drugs are right for these individuals, if it improves bone strength or are actually doing harm. Bone density measurement is of limited value. We have developed a new analysis method that measures changes in bone structure that tell us if the treatment is or is not working so alternative treatment can be used. The aim of this study is to test this new method.
Osteoporosis is the commonest metabolic bone disease worldwide, and costs Australia >1% of GDP. It is a strongly inherited disease. We recently completed a genome-wide association study in 2000 postmenopausal women with either very high or very low bone density, and identified many genes contributing to BMD. The current study aims to use next-generation sequencing to study these women in greater genetic depth, aiming to identify more clearly the exact genetic determinants of bone mass.
Obesity And Protective Properties Of High-Density Lipoproteins
Funder
National Health and Medical Research Council
Funding Amount
$391,265.00
Summary
High-density lipoproteins (HDL) are the good form of cholesterol and protect against heart disease. Obesity is associated with a high risk of heart disease and low HDL levels. The effects of obesity on the ability of HDL to prevent plaque build up in the artery wall has not been studied. This project will study how obesity affects the ability of HDL to stop plaque formation. This will provide important information linking two major health problems in Australia, obesity and heart disease.
Bisphosphonate Therapy With Zoledronate Or Tenofovir Switching To Improve Low Bone Mineral Density In HIV-Infected Adults: A Strategic, Randomised Trial
Funder
National Health and Medical Research Council
Funding Amount
$716,300.00
Summary
Most HIV+ Australians receive tenofovir, a ‘preferred’ drug in all HIV treatment guidelines, and may do for decades, as HIV therapy is lifelong and because there are very few new HIV drugs. 40% of HIV+ adults have low bone density and HIV+ adults experience more fractures. Of all HIV drugs, tenofovir causes the most bone loss. This trial compares two approaches: a drug to improve bone density and switching tenofovir to another drug. This ‘treat versus switch’ approach is a world-first for HIV.
Enhancing The Blood-brain Barrier Efflux Of ?-amyloid: A Novel Approach For The Treatment Of Alzheimer’s Disease
Funder
National Health and Medical Research Council
Funding Amount
$291,274.00
Summary
Alzheimer’s disease (AD) is the leading cause of dementia and is associated with the accumulation of a toxic protein in the brain. This project will investigate whether enhancing the removal of this toxic protein from the brain (by shuttling it into the blood) will restore the memory deficit associated with AD. The outcomes of this project have the potential to lead to novel strategies for the treatment of this debilitating disorder.
Long-term Effects Of Very Low Energy Diet Versus Conventional Diet On Adiposity, Lean Body Mass, Muscle Strength And Bone Density In Obese Adults, And Mechanisms Promoting Changes
Funder
National Health and Medical Research Council
Funding Amount
$925,990.00
Summary
Very low energy diets (VLEDs) are increasingly used to treat obesity. Of concern is the fact that VLEDs induce adaptive responses that can inhibit loss of – and promote regain of – fatness (particularly belly fat) while decreasing lean body mass, muscle strength and bone density. This project will therefore determine whether VLEDs could have negative effects on body composition that increase the risk of metabolic disease, sarcopenia or osteoporosis, and if so, what are the mechanisms involved.